The promotion of plasmacytoma tumor with growth by mesenchymal stroma is antagonized by basic fibroblast growth factor induced activin A

Leukemia

Volumn 15, Issue 7, 2001, Pages 1102-1110

  Shoham, T ^a   Sternberg, D ^a   Brosh, N ^a   Krupsky, M ^a   Barda Saad, M ^a   Zipori, D ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Activin A; bFGF; Plasmacytoma; Stroma

Indexed keywords

ACTIVIN A; BASIC FIBROBLAST GROWTH FACTOR; INTERLEUKIN 6; SOMATOMEDIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; GROWTH REGULATION; GROWTH STIMULATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MESENCHYME; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SERUM; SKIN TRANSPLANTATION; STROMA; STROMA CELL; TUMOR CELL; TUMOR CELL LINE; TUMOR GROWTH; TUMOR PROMOTION;

EID: 0034905554     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402145     Document Type: Article

References (64)

1. Stromal involvement in malignant growth
2. Stromal cells in tumor growth and regression
3. Cytokines and cancer
4. Conditions required for the inhibition of in vitro growth of a mouse myeloma cell line by adherent bone marrow cells
5. Interactions between leukemia cells and bone marrow stromal cells: Stroma-supported growth vs. serum dependence and the roles of TGF-beta and M-CSF
6. Homing mechanisms of myeloma cells
7. The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone
8. Adhesive interactions between tumour cells and bone marrow stromal elements in human multiple myeloma
9. Establishment and characterization of a human stroma-dependent myeloma cell line (MM5.1) and its stroma-independent variant (MM5.2)
10. Homing behaviour of the malignant cell clone in multiple myeloma
11. Multiple myeloma: Increasing evidence for a multistep transformation process
12. The somatostatin analog octreotide inhibits growth of interleukin-6 (IL-6)-dependent and IL-6-independent human multiple myeloma cell lines
13. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6
14. Cytokines as autocrine growth factors in malignancies
15. Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266
16. Fas/Fas ligand (FasL)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells
17. Stromal cell effects on clonal growth of tumors
18. Phenotypic heterogeneity among stromal cell lines from mouse bone marrow disclosed in their extracellular matrix composition and interactions with normal and leukemic cells
19. Differentiation stage and lineage-specific inhibitor from the stroma of mouse bone marrow that restricts lymphoma cell growth
20. The plasmacytoma growth inhibitor restrictin-P is an antagonist of interleukin 6 and interleukin 11. Identification as a stroma-derived activin A
21. Restrictin-P/stromal activin A, kills its target cells via an apoptotic mechanism
22. Activin A induces apoptotic cell death
23. Suppression of IL-6 biological activities by activin A and implications for inflammatory arthropathies
24. Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: Effects of dexamethasone and IL-1 alpha
25. Analysis of activin A gene expression in human bone marrow stromal cells
26. Regulation of production of activin A in human marrow stromal cells and monocytes
27. Cultured mouse marrow cell lines: Interactions between fibroblastoid cells and monocytes
28. Cultured mouse marrow stromal cell lines. II. Distinct subtypes differing in morphology, collagen types, myelopoietic factors, and leukemic cell growth modulating activities
29. Introduction of interleukin-3 gene into stromal cells from the bone marrow alters hemopoietic differentiation but does not modify stem cell renewal
30. Cultured stromal cell lines from hemopoietic tissues
31. Biochemistry of hybridoma technology
32. Structure, stability and biological properties of a N-terminally truncated form of recombinant human interleukin-6 containing a single disulfide bond
33. Expression cloning of an activin receptor, a predicted transmembrane serine kinase
34. Functional regulation of osteoblastic cells by the interaction of activin-A with follistatin
35. In vitro proliferation of mouse lymphoblastoid cell lines: Growth modulation by various populations of adherent cells
36. Bone marrow stromal cells produce and respond to activin A: Interactions with basic fibroblast growth factor and platelet-derived growth factor
37. Control of stroma-dependent hemopoiesis by basic fibroblast growth factor: Stromal phenotypic plasticity and modified myelopoietic functions
38. Expression of the c-kit ligand and interleukin 6 genes in mouse bone marrow stromal cell lines
39. Activin A and follistatin: Their role in the acute phase reaction and inflammation
40. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
41. Transforming growth factor-beta1: Differential effects on multiple myeloma versus normal B cells
42. Differential use of very late antigen-4 and -5 integrins by hematopoietic precursors and myeloma cells to adhere to transforming growth factor-beta1-treated bone marrow stroma
43. Inter-dependence between cytokines and cell adhesion molecules to induce interleukin-6 production by stromal cells in myeloma
44. Characterization of VLA-4-dependent myeloma cell adhesion to fibronectin and VCAM-1
45. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
46. Fas/APO-1 (CD95)-mediated apoptosis is activated by interferon-gamma and interferon-α in interleukin-6 (IL-6)-dependent and IL-6-independent multiple myeloma cell lines
47. Antitumor effects of interferon-omega: In vivo therapy of human tumor xenografts in nude mice
48. Corticotropin-releasing hormone stimulates angiogenesis and epithelial tumor growth in the skin
49. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4
50. + cells: Role in transendothelial/stromal migration and engraftment of NOD/SCID mice
51. Engraftment in nonobese diabetic severe combined immunodeficient mice of human CD34(+) cord blood cells after ex vivo expansion: Evidence for the amplification and self-renewal of repopulating stem cells
52. Transforming growth factor-beta: Recent progress and new challenges
53. Cooperative effects of growth factors involved in the induction of hematopoietic mesoderm
54. Erythroid differentiation factor is encoded by the same mRNA as that of the inhibin beta A chain
55. Activin A/erythroid differentiation factor is induced during human monocyte activation
56. Effects of activin A/erythroid differentiation factor on erythroid and megakaryocytic differentiations of mouse erythroleukemia (Friend) cells: Evidence for two distinct modes of cell response
57. Molecular determinants of angiogenesis in cancer metastasis
58. Basic fibroblast growth factor and epidermal growth factor downmodulate the growth of hematopoietic cells in long-term stromal cultures
59. Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells
60. The expression of basic fibroblast growth factor (bFGF) in tumor-associated stromal cells and vessels is inversely correlated with non-small cell lung cancer progression
61. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
62. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis
63. Treatment of multiple myeloma
64. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: A population-based study